CTLA4 and hepatocellular carcinoma: Dasatinib, an indirect STAT3 inhibitor against SRC/ABL, significantly facilitated anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma [115], while the combined blockade of IL-6 and PD-L1 remarkably inhibited the growth of pancreatic ductal adenocarcinoma and hepatocellular carcinoma (HCC) [167, 168].